摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine

中文名称
——
中文别名
——
英文名称
4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine
英文别名
——
4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine化学式
CAS
——
化学式
C8H10ClN5
mdl
——
分子量
211.654
InChiKey
WEEOGHYWTLXMOS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.64
  • 重原子数:
    14.0
  • 可旋转键数:
    1.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    69.62
  • 氢给体数:
    1.0
  • 氢受体数:
    5.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists
    摘要:
    An efficient synthetic procedure was adopted to synthesize a series of new molecules containing the pyrazolo[3,4-d]pyrimidine (PP) scaffold, which have been evaluated as promising human adenosine receptor (AR) antagonists. The effect of substitutions at the N-2, C-4 and C-6 positions of PPs on the affinity and selectivity towards the adenosine receptors were explored. Most of the pyrazolo[3,4-d]pyrimidine-4-carboxylates displayed from moderate to good affinity at the human A(3)AR (hA(3)AR), as indicated by the low micromolar range of K-i values (K-i hA(3)AR = 0.7-34 mu M). In particular, compounds 60 and 62 displayed good affinity at the hA(3)AR (60, K-i hA(3)AR = 2.2 mu M and 62, K-i hA(3)AR = 2.9 mu M) and selectivity towards the other AR subtypes (60, >46-fold selective and 62, >34-fold selective, respectively). In view of these results, these novel PP analogues were docked both in the crystallographic structure of the hA(2A)AR and in a homology model of the hA(3)AR in order to support the structure activity relationship (SAR) analysis. These preliminary results demonstrated that pyrazolo[3,4-d]pyrimidine can be considered a promising scaffold to obtain new molecules with potent hA(3)AR antagonist activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.01.046
  • 作为产物:
    描述:
    3-氨基-1-异丙基-1H-吡唑-4-甲腈硫酸二甲胺 、 sodium hydroxide 、 三氯化磷 作用下, 以 N,N-二甲基甲酰胺丙酮 为溶剂, 反应 59.0h, 生成 4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine
    参考文献:
    名称:
    发现简化的N 2取代的吡唑并[3,4- d ]嘧啶衍生物作为新型腺苷受体拮抗剂:有效的合成方法,生物学评估和分子对接研究
    摘要:
    在本研究中,采用了这样的分子的简化的方法来设计新的双环吡唑并[3,4- d ]从三环吡唑并嘧啶(PP)衍生物[4,3- ë ] -1,2,4-三唑并[1, 5- c ]嘧啶(PTP)作为有前途的人类A 3腺苷受体(hA 3 AR)拮抗剂。使用新颖有效的合成方案合成了所有目标化合物,并且通过合成一系列具有各种取代基的PTP类似物,探索了这些PP的结构-活性关系研究。在N 2处引入了具有不同亲脂性和空间位阻(例如烷基和芳基-烷基)功能的取代基吡唑环的位置,而在双环核的C 6位置引入具有不同电子性质的酰基,以探测电子和位置效应。大部分的PP系列的合成衍生物的呈现良好的亲和力在HA 3 AR,由低微摩尔范围内的所指示ķ我值和它们之间,化合物63用N 2个的新戊取代基显示最有效的HA 3与AR的亲和力ķ我0.9μM的值和高选择性(hA 1 AR / hA 3 AR => 111&hA 2A AR /
    DOI:
    10.1016/j.bmc.2014.01.018
点击查看最新优质反应信息

文献信息

  • Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies
    作者:Gopalakrishnan Venkatesan、Priyankar Paira、Siew Lee Cheong、Kosaraju Vamsikrishna、Stephanie Federico、Karl-Norbert Klotz、Giampiero Spalluto、Giorgia Pastorin
    DOI:10.1016/j.bmc.2014.01.018
    日期:2014.3
    employed to design novel bicyclic pyrazolo[3,4-d]pyrimidine (PP) derivatives from tricyclic pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines (PTP) as promising human A3 adenosine receptor (hA3AR) antagonists. All the target compounds were synthesized using novel and efficient synthetic schemes and the structure–activity relationship studies of these PPs were explored through the synthesis of a series of
    在本研究中,采用了这样的分子的简化的方法来设计新的双环吡唑并[3,4- d ]从三环吡唑并嘧啶(PP)衍生物[4,3- ë ] -1,2,4-三唑并[1, 5- c ]嘧啶(PTP)作为有前途的人类A 3腺苷受体(hA 3 AR)拮抗剂。使用新颖有效的合成方案合成了所有目标化合物,并且通过合成一系列具有各种取代基的PTP类似物,探索了这些PP的结构-活性关系研究。在N 2处引入了具有不同亲脂性和空间位阻(例如烷基和芳基-烷基)功能的取代基吡唑环的位置,而在双环核的C 6位置引入具有不同电子性质的酰基,以探测电子和位置效应。大部分的PP系列的合成衍生物的呈现良好的亲和力在HA 3 AR,由低微摩尔范围内的所指示ķ我值和它们之间,化合物63用N 2个的新戊取代基显示最有效的HA 3与AR的亲和力ķ我0.9μM的值和高选择性(hA 1 AR / hA 3 AR => 111&hA 2A AR /
  • A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists
    作者:G. Venkatesan、P. Paira、S.L. Cheong、S. Federico、K.N. Klotz、G. Spalluto、G. Pastorin
    DOI:10.1016/j.ejmech.2015.01.046
    日期:2015.3
    An efficient synthetic procedure was adopted to synthesize a series of new molecules containing the pyrazolo[3,4-d]pyrimidine (PP) scaffold, which have been evaluated as promising human adenosine receptor (AR) antagonists. The effect of substitutions at the N-2, C-4 and C-6 positions of PPs on the affinity and selectivity towards the adenosine receptors were explored. Most of the pyrazolo[3,4-d]pyrimidine-4-carboxylates displayed from moderate to good affinity at the human A(3)AR (hA(3)AR), as indicated by the low micromolar range of K-i values (K-i hA(3)AR = 0.7-34 mu M). In particular, compounds 60 and 62 displayed good affinity at the hA(3)AR (60, K-i hA(3)AR = 2.2 mu M and 62, K-i hA(3)AR = 2.9 mu M) and selectivity towards the other AR subtypes (60, >46-fold selective and 62, >34-fold selective, respectively). In view of these results, these novel PP analogues were docked both in the crystallographic structure of the hA(2A)AR and in a homology model of the hA(3)AR in order to support the structure activity relationship (SAR) analysis. These preliminary results demonstrated that pyrazolo[3,4-d]pyrimidine can be considered a promising scaffold to obtain new molecules with potent hA(3)AR antagonist activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺